{
    "info": {
        "nct_id": "NCT05182905",
        "official_title": "A Phase 0/1b, Single Center, Clinical Trial with an Expansion Phase of AZD1390 Plus Fractionated Radiotherapy in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients",
        "inclusion_criteria": "1a. Arm C only: Participants undergoing resection for a suspected newly diagnosed WHO Grade 4 glioma. Participants will also need to have radiation planned as part of the post-surgical treatment plan; OR,\n\n1b. Arms A and B only: Participants who have had a prior resection of diagnosed glioma (2021 WHO grade IV), defined as participants who have progressed on or following standard therapy, which includes maximal surgical resection, temozolomide, and fractionated radiotherapy. Participants will also need to have radiation planned as part of the post-surgical treatment plan.\n\n2. Participants must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm.\n\n3. Provision of signed and dated, written informed consent (personally or by the legally authorized representative, if applicable) prior to any study specific procedures, sampling and analyses.\n\n4. Age ≥18 at time of consent. 5. Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology (Group (ECOG) scale1.\n\n6. Ability to swallow oral medications. 7. Participant has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility):\n\n* Adequate bone marrow function:\n\n  * absolute neutrophil count ≥1,500/mcL\n  * Platelets (at time of surgery) ≥100,000/mcL\n  * hemoglobin ≥9.0 g/dL Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.\n* Adequate hepatic function:\n\n  o total bilirubin ≤1.5 X ULN. Participants with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.\n\n  o AST(SGOT) ≤2.5 X institutional ULN\n\n  o ALT(SGPT) ≤2.5 X institutional ULN\n* Adequate pancreatic function:\n\n  o Amylase within normal limits (WNL)\n\n  o Lipase within normal limits (WNL)\n* Adequate renal function:\n\n  * Serum creatinine ≤1.5 X ULN or estimated creatinine clearance ≥ 60 mL/min (calculated using Institutional standard method) 8. Participants with tumor-induced seizures must be well-controlled on a stable anti-epileptic treatment.\n\n    9. Participants must be willing to receive prophylaxis with levetiracetam for the duration of study drug administration (or alternative anti-epileptic if agreed with Medical Monitor) 10. Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause.\n\n    11. For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation until the end of treatment administration and for 16 weeks after the last dose of study drug.\n\n    12. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner until the end of treatment administration and for 16 weeks after the last dose of study drug.\n\n    13. Agreement to adhere to Lifestyle Considerations (see Section 5.3) throughout study duration.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Current use of coumarin-derived anticoagulant for treatment, prophylaxis or otherwise, that cannot be discontinued prior to surgery. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.\n2. Pregnancy or lactation.\n3. Known allergic reactions to components of the AZD1390.\n4. Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis, as determined by the investigator.\n5. Known active systemic bacterial infection (requiring intravenous [IV] antibiotics or fever >38.5°C at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening of viral infection is not required for enrollment.\n6. The participant has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.\n7. Any of the following cardiac criteria:\n\n   * Cardiac dysfunction defined as: Myocardial infarction within six months of study entry, NYHA Class II/III/IV heart failure, unstable angina or unstable cardiac arrhythmias.\n   * Mean resting corrected QT interval (QTcF) > 470 msec obtained from 3 electrocardiograms (ECGs) (QTc interval will be calculated using Fridericia's formula).\n   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block.\n   * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age. Patients stable on concomitant medications known to prolong the QT interval may be allowed to participate in the study provided that their mean resting corrected QT interval (QTcF) is < 470 msec at baseline and after discussion with the Medical Monitor.\n8. History of epileptic disorder or any seizure history unrelated to tumor.\n9. History or presence of myopathy or raised creatine kinase (CK) >5 x upper limit of normal (ULN) on 2 occasions at screening.\n10. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n11. Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).\n12. Prior therapy with ATM kinase inhibitors.\n13. Treatment with strong inhibitors or inducers of CYP3A4 within 2 weeks prior to receiving study drug.\n14. Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year. If prior therapy in lifetime, then excluded if history of pulmonary toxicities from administration. Patients who have received treatment with nitrosoureas (e.g., BCNU, CCNU) in the year before study entry without experiencing lung toxicity are allowed on study.\n15. Treatment with another investigational drug or other intervention within 5 half-lives of the investigational product, whichever is longer.\n16. With the exception of alopecia, any unresolved toxicities from prior therapy greater than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) Grade 1 at the time of starting study treatment and patients with chronic Grade 2 unresolved toxicities may be eligible following discussion with the Medical Monitor.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "o AST(SGOT) ≤2.5 X institutional ULN",
                "criterions": [
                    {
                        "exact_snippets": "AST(SGOT) ≤2.5 X institutional ULN",
                        "criterion": "AST (SGOT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x institutional ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "AST(SGOT) ≤2.5 X institutional ULN",
                        "criterion": "AST (SGOT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x institutional ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Agreement to adhere to Lifestyle Considerations (see Section 5.3) throughout study duration.",
                "criterions": [
                    {
                        "exact_snippets": "Agreement to adhere to Lifestyle Considerations (see Section 5.3) throughout study duration.",
                        "criterion": "adherence to Lifestyle Considerations",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Agreement to adhere to Lifestyle Considerations (see Section 5.3) throughout study duration.",
                        "criterion": "adherence to Lifestyle Considerations",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "throughout study duration"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Agreement to adhere to Lifestyle Considerations (see Section 5.3) throughout study duration.",
                        "criterion": "adherence to Lifestyle Considerations",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Agreement to adhere to Lifestyle Considerations (see Section 5.3) throughout study duration.",
                        "criterion": "adherence to Lifestyle Considerations",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "throughout study duration"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "o Amylase within normal limits (WNL)",
                "criterions": [
                    {
                        "exact_snippets": "Amylase within normal limits (WNL)",
                        "criterion": "amylase",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "within normal limits"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Amylase within normal limits (WNL)",
                        "criterion": "amylase",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "within normal limits"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Ability to swallow oral medications. 7. Participant has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility):",
                "criterions": [
                    {
                        "exact_snippets": "Ability to swallow oral medications",
                        "criterion": "ability to swallow oral medications",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adequate bone marrow and organ function as defined by the following laboratory values",
                        "criterion": "bone marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adequate bone marrow and organ function as defined by the following laboratory values",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ability to swallow oral medications",
                        "criterion": "ability to swallow oral medications",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adequate bone marrow and organ function as defined by the following laboratory values",
                        "criterion": "bone marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adequate bone marrow and organ function as defined by the following laboratory values",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Adequate renal function:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate renal function",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate renal function",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "o Lipase within normal limits (WNL)",
                "criterions": [
                    {
                        "exact_snippets": "Lipase within normal limits (WNL)",
                        "criterion": "lipase",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "within normal limits"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Lipase within normal limits (WNL)",
                        "criterion": "lipase",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "within normal limits"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Participants must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm.",
                "criterions": [
                    {
                        "exact_snippets": "Participants must have measurable disease preoperatively",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "at least 1 contrast-enhancing lesion",
                        "criterion": "contrast-enhancing lesion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "2 perpendicular measurements of at least 1 cm",
                        "criterion": "lesion size (perpendicular measurements)",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "cm"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "cm"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants must have measurable disease preoperatively",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "at least 1 contrast-enhancing lesion",
                        "criterion": "contrast-enhancing lesion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "2 perpendicular measurements of at least 1 cm",
                        "criterion": "lesion size (perpendicular measurements)",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "cm"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "cm"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* absolute neutrophil count ≥1,500/mcL",
                "criterions": [
                    {
                        "exact_snippets": "absolute neutrophil count ≥1,500/mcL",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mcL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "absolute neutrophil count ≥1,500/mcL",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mcL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Adequate hepatic function:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate hepatic function",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate hepatic function",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "o ALT(SGPT) ≤2.5 X institutional ULN",
                "criterions": [
                    {
                        "exact_snippets": "ALT(SGPT) ≤2.5 X institutional ULN",
                        "criterion": "ALT (SGPT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "institutional ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ALT(SGPT) ≤2.5 X institutional ULN",
                        "criterion": "ALT (SGPT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "institutional ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Provision of signed and dated, written informed consent (personally or by the legally authorized representative, if applicable) prior to any study specific procedures, sampling and analyses.",
                "criterions": [
                    {
                        "exact_snippets": "Provision of signed and dated, written informed consent (personally or by the legally authorized representative, if applicable) prior to any study specific procedures, sampling and analyses.",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Provision of signed and dated, written informed consent (personally or by the legally authorized representative, if applicable) prior to any study specific procedures, sampling and analyses.",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed and dated",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Provision of signed and dated, written informed consent (personally or by the legally authorized representative, if applicable) prior to any study specific procedures, sampling and analyses.",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to any study specific procedures, sampling and analyses"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Provision of signed and dated, written informed consent (personally or by the legally authorized representative, if applicable) prior to any study specific procedures, sampling and analyses.",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Provision of signed and dated, written informed consent (personally or by the legally authorized representative, if applicable) prior to any study specific procedures, sampling and analyses.",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed and dated",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Provision of signed and dated, written informed consent (personally or by the legally authorized representative, if applicable) prior to any study specific procedures, sampling and analyses.",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to any study specific procedures, sampling and analyses"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Adequate pancreatic function:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate pancreatic function",
                        "criterion": "pancreatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate pancreatic function",
                        "criterion": "pancreatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Age ≥18 at time of consent. 5. Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology (Group (ECOG) scale1.",
                "criterions": [
                    {
                        "exact_snippets": "Age ≥18 at time of consent",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "performance status (PS) of ≤2 on the Eastern Cooperative Oncology (Group (ECOG) scale",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "ECOG scale"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age ≥18 at time of consent",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "performance status (PS) of ≤2 on the Eastern Cooperative Oncology (Group (ECOG) scale",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "ECOG scale"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Adequate bone marrow function:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate bone marrow function",
                        "criterion": "bone marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate bone marrow function",
                        "criterion": "bone marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1a. Arm C only: Participants undergoing resection for a suspected newly diagnosed WHO Grade 4 glioma. Participants will also need to have radiation planned as part of the post-surgical treatment plan; OR,",
                "criterions": [
                    {
                        "exact_snippets": "Arm C only",
                        "criterion": "study arm",
                        "requirement": {
                            "requirement_type": "assignment",
                            "expected_value": "Arm C"
                        }
                    },
                    {
                        "exact_snippets": "Participants undergoing resection for a suspected newly diagnosed WHO Grade 4 glioma",
                        "criterion": "surgical resection for suspected newly diagnosed WHO Grade 4 glioma",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": "undergoing resection"
                        }
                    },
                    {
                        "exact_snippets": "Participants undergoing resection for a suspected newly diagnosed WHO Grade 4 glioma",
                        "criterion": "surgical resection for suspected newly diagnosed WHO Grade 4 glioma",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "suspected newly diagnosed WHO Grade 4 glioma"
                        }
                    },
                    {
                        "exact_snippets": "radiation planned as part of the post-surgical treatment plan",
                        "criterion": "post-surgical radiation therapy",
                        "requirement": {
                            "requirement_type": "treatment plan",
                            "expected_value": "radiation planned post-surgery"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Arm C only",
                                "criterion": "study arm",
                                "requirement": {
                                    "requirement_type": "assignment",
                                    "expected_value": "Arm C"
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Participants undergoing resection for a suspected newly diagnosed WHO Grade 4 glioma",
                                        "criterion": "surgical resection for suspected newly diagnosed WHO Grade 4 glioma",
                                        "requirement": {
                                            "requirement_type": "procedure",
                                            "expected_value": "undergoing resection"
                                        }
                                    },
                                    {
                                        "exact_snippets": "Participants undergoing resection for a suspected newly diagnosed WHO Grade 4 glioma",
                                        "criterion": "surgical resection for suspected newly diagnosed WHO Grade 4 glioma",
                                        "requirement": {
                                            "requirement_type": "diagnosis",
                                            "expected_value": "suspected newly diagnosed WHO Grade 4 glioma"
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "radiation planned as part of the post-surgical treatment plan",
                                "criterion": "post-surgical radiation therapy",
                                "requirement": {
                                    "requirement_type": "treatment plan",
                                    "expected_value": "radiation planned post-surgery"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "6. The participant has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.",
                "criterions": [
                    {
                        "exact_snippets": "personal history of ... syncope of cardiovascular etiology",
                        "criterion": "syncope of cardiovascular etiology",
                        "requirement": {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "personal history of ... ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation)",
                        "criterion": "ventricular arrhythmia of pathological origin",
                        "requirement": {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "personal history of ... sudden cardiac arrest",
                        "criterion": "sudden cardiac arrest",
                        "requirement": {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "personal history of ... syncope of cardiovascular etiology",
                        "criterion": "syncope of cardiovascular etiology",
                        "requirement": {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "personal history of ... ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation)",
                        "criterion": "ventricular arrhythmia of pathological origin",
                        "requirement": {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "personal history of ... sudden cardiac arrest",
                        "criterion": "sudden cardiac arrest",
                        "requirement": {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Treatment with strong inhibitors or inducers of CYP3A4 within 2 weeks prior to receiving study drug.",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with strong inhibitors or inducers of CYP3A4 within 2 weeks prior to receiving study drug.",
                        "criterion": "treatment with strong inhibitors or inducers of CYP3A4",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Treatment with strong inhibitors or inducers of CYP3A4 within 2 weeks prior to receiving study drug.",
                        "criterion": "treatment with strong inhibitors or inducers of CYP3A4",
                        "requirement": {
                            "requirement_type": "timing_context",
                            "expected_value": "prior to receiving study drug"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Treatment with strong inhibitors or inducers of CYP3A4 within 2 weeks prior to receiving study drug.",
                        "criterion": "treatment with strong inhibitors or inducers of CYP3A4",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Treatment with strong inhibitors or inducers of CYP3A4 within 2 weeks prior to receiving study drug.",
                        "criterion": "treatment with strong inhibitors or inducers of CYP3A4",
                        "requirement": {
                            "requirement_type": "timing_context",
                            "expected_value": "prior to receiving study drug"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. With the exception of alopecia, any unresolved toxicities from prior therapy greater than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) Grade 1 at the time of starting study treatment and patients with chronic Grade 2 unresolved toxicities may be eligible following discussion with the Medical Monitor.",
                "criterions": [
                    {
                        "exact_snippets": "any unresolved toxicities from prior therapy greater than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) Grade 1 at the time of starting study treatment",
                        "criterion": "unresolved toxicities from prior therapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "NCI CTCAE v5.0 Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "patients with chronic Grade 2 unresolved toxicities may be eligible following discussion with the Medical Monitor",
                        "criterion": "chronic Grade 2 unresolved toxicities",
                        "requirement": {
                            "requirement_type": "eligibility after discussion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "any unresolved toxicities from prior therapy greater than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) Grade 1 at the time of starting study treatment",
                                    "criterion": "unresolved toxicities from prior therapy",
                                    "requirement": {
                                        "requirement_type": "severity",
                                        "expected_value": {
                                            "operator": "<=",
                                            "value": 1,
                                            "unit": "NCI CTCAE v5.0 Grade"
                                        }
                                    }
                                },
                                {
                                    "not_criteria": {
                                        "exact_snippets": "patients with chronic Grade 2 unresolved toxicities may be eligible following discussion with the Medical Monitor",
                                        "criterion": "chronic Grade 2 unresolved toxicities",
                                        "requirement": {
                                            "requirement_type": "eligibility after discussion",
                                            "expected_value": true
                                        }
                                    }
                                }
                            ]
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "any unresolved toxicities from prior therapy greater than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) Grade 1 at the time of starting study treatment",
                            "criterion": "unresolved toxicities from prior therapy",
                            "requirement": {
                                "requirement_type": "severity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 1,
                                    "unit": "NCI CTCAE v5.0 Grade"
                                }
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.",
                "criterions": [
                    {
                        "exact_snippets": "Past medical history of interstitial lung disease (ILD)",
                        "criterion": "interstitial lung disease (ILD)",
                        "requirement": {
                            "requirement_type": "past medical history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "drug-induced ILD",
                        "criterion": "drug-induced interstitial lung disease (ILD)",
                        "requirement": {
                            "requirement_type": "past medical history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "radiation pneumonitis which required steroid treatment",
                        "criterion": "radiation pneumonitis",
                        "requirement": {
                            "requirement_type": "past medical history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "radiation pneumonitis which required steroid treatment",
                        "criterion": "radiation pneumonitis",
                        "requirement": {
                            "requirement_type": "required steroid treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any evidence of clinically active interstitial lung disease",
                        "criterion": "clinically active interstitial lung disease",
                        "requirement": {
                            "requirement_type": "evidence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Past medical history of interstitial lung disease (ILD)",
                                "criterion": "interstitial lung disease (ILD)",
                                "requirement": {
                                    "requirement_type": "past medical history",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "drug-induced ILD",
                                "criterion": "drug-induced interstitial lung disease (ILD)",
                                "requirement": {
                                    "requirement_type": "past medical history",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "radiation pneumonitis which required steroid treatment",
                                "criterion": "radiation pneumonitis",
                                "requirement": {
                                    "requirement_type": "past medical history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "radiation pneumonitis which required steroid treatment",
                                "criterion": "radiation pneumonitis",
                                "requirement": {
                                    "requirement_type": "required steroid treatment",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "any evidence of clinically active interstitial lung disease",
                                "criterion": "clinically active interstitial lung disease",
                                "requirement": {
                                    "requirement_type": "evidence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block.",
                "criterions": [
                    {
                        "exact_snippets": "Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormalities in rhythm",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormalities in conduction",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormalities in morphology",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "complete left bundle branch block",
                        "criterion": "left bundle branch block",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "third degree heart block",
                        "criterion": "heart block",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": "third"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                                "criterion": "resting ECG",
                                "requirement": {
                                    "requirement_type": "abnormalities in rhythm",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                                "criterion": "resting ECG",
                                "requirement": {
                                    "requirement_type": "abnormalities in conduction",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                                "criterion": "resting ECG",
                                "requirement": {
                                    "requirement_type": "abnormalities in morphology",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "complete left bundle branch block",
                        "criterion": "left bundle branch block",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "third degree heart block",
                        "criterion": "heart block",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": "third"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).",
                "criterions": [
                    {
                        "exact_snippets": "serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study",
                        "criterion": "preexisting medical condition",
                        "requirement": {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study",
                        "criterion": "preexisting medical condition",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "interstitial lung disease",
                        "criterion": "interstitial lung disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "severe dyspnea at rest or requiring oxygen therapy",
                        "criterion": "dyspnea",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "severe dyspnea at rest or requiring oxygen therapy",
                        "criterion": "dyspnea",
                        "requirement": {
                            "requirement_type": "at_rest",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "severe dyspnea at rest or requiring oxygen therapy",
                        "criterion": "oxygen therapy requirement",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "severe renal impairment [e.g. estimated creatinine clearance <30ml/min]",
                        "criterion": "renal impairment",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "estimated creatinine clearance <30ml/min",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of major surgical resection involving the stomach or small bowel",
                        "criterion": "major surgical resection involving the stomach or small bowel",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "preexisting Crohn's disease or ulcerative colitis",
                        "criterion": "Crohn's disease",
                        "requirement": {
                            "requirement_type": "preexisting",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "preexisting Crohn's disease or ulcerative colitis",
                        "criterion": "ulcerative colitis",
                        "requirement": {
                            "requirement_type": "preexisting",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea",
                        "criterion": "chronic condition resulting in diarrhea",
                        "requirement": {
                            "requirement_type": "diarrhea_grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study",
                                "criterion": "preexisting medical condition",
                                "requirement": {
                                    "requirement_type": "seriousness",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study",
                                "criterion": "preexisting medical condition",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "interstitial lung disease",
                        "criterion": "interstitial lung disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "severe dyspnea at rest or requiring oxygen therapy",
                                "criterion": "dyspnea",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "severe"
                                }
                            },
                            {
                                "exact_snippets": "severe dyspnea at rest or requiring oxygen therapy",
                                "criterion": "dyspnea",
                                "requirement": {
                                    "requirement_type": "at_rest",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "severe dyspnea at rest or requiring oxygen therapy",
                                "criterion": "oxygen therapy requirement",
                                "requirement": {
                                    "requirement_type": "requirement",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "severe renal impairment [e.g. estimated creatinine clearance <30ml/min]",
                                "criterion": "renal impairment",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "severe"
                                }
                            },
                            {
                                "exact_snippets": "estimated creatinine clearance <30ml/min",
                                "criterion": "creatinine clearance",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 30,
                                        "unit": "ml/min"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "history of major surgical resection involving the stomach or small bowel",
                        "criterion": "major surgical resection involving the stomach or small bowel",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "preexisting Crohn's disease or ulcerative colitis",
                                "criterion": "Crohn's disease",
                                "requirement": {
                                    "requirement_type": "preexisting",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "preexisting Crohn's disease or ulcerative colitis",
                                "criterion": "ulcerative colitis",
                                "requirement": {
                                    "requirement_type": "preexisting",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea",
                        "criterion": "chronic condition resulting in diarrhea",
                        "requirement": {
                            "requirement_type": "diarrhea_grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. History of epileptic disorder or any seizure history unrelated to tumor.",
                "criterions": [
                    {
                        "exact_snippets": "History of epileptic disorder",
                        "criterion": "epileptic disorder",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any seizure history unrelated to tumor",
                        "criterion": "seizure history unrelated to tumor",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of epileptic disorder",
                        "criterion": "epileptic disorder",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any seizure history unrelated to tumor",
                        "criterion": "seizure history unrelated to tumor",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. Treatment with another investigational drug or other intervention within 5 half-lives of the investigational product, whichever is longer.",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with another investigational drug or other intervention within 5 half-lives of the investigational product, whichever is longer.",
                        "criterion": "treatment with another investigational drug or other intervention",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "half-lives of the investigational product"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Treatment with another investigational drug or other intervention within 5 half-lives of the investigational product, whichever is longer.",
                    "criterion": "treatment with another investigational drug or other intervention",
                    "requirement": {
                        "requirement_type": "time since last treatment",
                        "expected_value": {
                            "operator": ">",
                            "value": 5,
                            "unit": "half-lives of the investigational product"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "12. Prior therapy with ATM kinase inhibitors.",
                "criterions": [
                    {
                        "exact_snippets": "Prior therapy with ATM kinase inhibitors.",
                        "criterion": "prior therapy with ATM kinase inhibitors",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Prior therapy with ATM kinase inhibitors.",
                    "criterion": "prior therapy with ATM kinase inhibitors",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis, as determined by the investigator.",
                "criterions": [
                    {
                        "exact_snippets": "Known to have active (acute or chronic) or uncontrolled severe infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known to have active (acute or chronic) or uncontrolled severe infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Known to have active (acute or chronic) or uncontrolled severe infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "liver disease such as cirrhosis, decompensated liver disease",
                        "criterion": "liver disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active and chronic hepatitis",
                        "criterion": "hepatitis",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active and chronic hepatitis",
                        "criterion": "hepatitis",
                        "requirement": {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Known to have active (acute or chronic) or uncontrolled severe infection",
                                        "criterion": "infection",
                                        "requirement": {
                                            "requirement_type": "activity",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Known to have active (acute or chronic) or uncontrolled severe infection",
                                        "criterion": "infection",
                                        "requirement": {
                                            "requirement_type": "control",
                                            "expected_value": false
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Known to have active (acute or chronic) or uncontrolled severe infection",
                                        "criterion": "infection",
                                        "requirement": {
                                            "requirement_type": "activity",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Known to have active (acute or chronic) or uncontrolled severe infection",
                                        "criterion": "infection",
                                        "requirement": {
                                            "requirement_type": "severity",
                                            "expected_value": "severe"
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "exact_snippets": "liver disease such as cirrhosis, decompensated liver disease",
                        "criterion": "liver disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "active and chronic hepatitis",
                                "criterion": "hepatitis",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "active and chronic hepatitis",
                                "criterion": "hepatitis",
                                "requirement": {
                                    "requirement_type": "chronicity",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Mean resting corrected QT interval (QTcF) > 470 msec obtained from 3 electrocardiograms (ECGs) (QTc interval will be calculated using Fridericia's formula).",
                "criterions": [
                    {
                        "exact_snippets": "Mean resting corrected QT interval (QTcF) > 470 msec",
                        "criterion": "mean resting corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    },
                    {
                        "exact_snippets": "obtained from 3 electrocardiograms (ECGs)",
                        "criterion": "number of electrocardiograms (ECGs) used to obtain QTcF",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "ECGs"
                            }
                        }
                    },
                    {
                        "exact_snippets": "QTc interval will be calculated using Fridericia's formula",
                        "criterion": "QTc interval calculation method",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Fridericia's formula"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Mean resting corrected QT interval (QTcF) > 470 msec",
                        "criterion": "mean resting corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    },
                    {
                        "exact_snippets": "obtained from 3 electrocardiograms (ECGs)",
                        "criterion": "number of electrocardiograms (ECGs) used to obtain QTcF",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "ECGs"
                            }
                        }
                    },
                    {
                        "exact_snippets": "QTc interval will be calculated using Fridericia's formula",
                        "criterion": "QTc interval calculation method",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Fridericia's formula"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Current use of coumarin-derived anticoagulant for treatment, prophylaxis or otherwise, that cannot be discontinued prior to surgery. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.",
                "criterions": [
                    {
                        "exact_snippets": "Current use of coumarin-derived anticoagulant ... that cannot be discontinued prior to surgery",
                        "criterion": "coumarin-derived anticoagulant use",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current use of coumarin-derived anticoagulant ... that cannot be discontinued prior to surgery",
                        "criterion": "coumarin-derived anticoagulant use",
                        "requirement": {
                            "requirement_type": "discontinuation prior to surgery",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Current use of coumarin-derived anticoagulant ... that cannot be discontinued prior to surgery",
                        "criterion": "coumarin-derived anticoagulant use",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current use of coumarin-derived anticoagulant ... that cannot be discontinued prior to surgery",
                        "criterion": "coumarin-derived anticoagulant use",
                        "requirement": {
                            "requirement_type": "discontinuation prior to surgery",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. History or presence of myopathy or raised creatine kinase (CK) >5 x upper limit of normal (ULN) on 2 occasions at screening.",
                "criterions": [
                    {
                        "exact_snippets": "History or presence of myopathy",
                        "criterion": "myopathy",
                        "requirement": {
                            "requirement_type": "history_or_presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "raised creatine kinase (CK) >5 x upper limit of normal (ULN) on 2 occasions at screening",
                        "criterion": "creatine kinase (CK) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "raised creatine kinase (CK) >5 x upper limit of normal (ULN) on 2 occasions at screening",
                        "criterion": "creatine kinase (CK) level",
                        "requirement": {
                            "requirement_type": "frequency",
                            "expected_value": "on 2 occasions at screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History or presence of myopathy",
                        "criterion": "myopathy",
                        "requirement": {
                            "requirement_type": "history_or_presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "raised creatine kinase (CK) >5 x upper limit of normal (ULN) on 2 occasions at screening",
                                "criterion": "creatine kinase (CK) level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "raised creatine kinase (CK) >5 x upper limit of normal (ULN) on 2 occasions at screening",
                                "criterion": "creatine kinase (CK) level",
                                "requirement": {
                                    "requirement_type": "frequency",
                                    "expected_value": "on 2 occasions at screening"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Any of the following cardiac criteria:",
                "criterions": [
                    {
                        "exact_snippets": "Any of the following cardiac criteria",
                        "criterion": "cardiac criteria",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any of the following cardiac criteria",
                        "criterion": "cardiac criteria",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Known allergic reactions to components of the AZD1390.",
                "criterions": [
                    {
                        "exact_snippets": "Known allergic reactions to components of the AZD1390",
                        "criterion": "allergic reactions to components of AZD1390",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Known allergic reactions to components of the AZD1390",
                    "criterion": "allergic reactions to components of AZD1390",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "5. Known active systemic bacterial infection (requiring intravenous [IV] antibiotics or fever >38.5°C at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening of viral infection is not required for enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Known active systemic bacterial infection (requiring intravenous [IV] antibiotics or fever >38.5°C at time of initiating study treatment)",
                        "criterion": "active systemic bacterial infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known active systemic bacterial infection (requiring intravenous [IV] antibiotics or fever >38.5°C at time of initiating study treatment)",
                        "criterion": "active systemic bacterial infection",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring intravenous [IV] antibiotics"
                        }
                    },
                    {
                        "exact_snippets": "Known active systemic bacterial infection (requiring intravenous [IV] antibiotics or fever >38.5°C at time of initiating study treatment)",
                        "criterion": "active systemic bacterial infection",
                        "requirement": {
                            "requirement_type": "associated symptom",
                            "expected_value": {
                                "operator": ">",
                                "value": 38.5,
                                "unit": "°C"
                            }
                        }
                    },
                    {
                        "exact_snippets": "fungal infection",
                        "criterion": "fungal infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]",
                        "criterion": "detectable viral infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known human immunodeficiency virus positivity",
                        "criterion": "human immunodeficiency virus (HIV) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known active hepatitis B or C [for example, hepatitis B surface antigen positive]",
                        "criterion": "active hepatitis B or C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Known active systemic bacterial infection (requiring intravenous [IV] antibiotics or fever >38.5°C at time of initiating study treatment)",
                                "criterion": "active systemic bacterial infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "Known active systemic bacterial infection (requiring intravenous [IV] antibiotics or fever >38.5°C at time of initiating study treatment)",
                                        "criterion": "active systemic bacterial infection",
                                        "requirement": {
                                            "requirement_type": "treatment requirement",
                                            "expected_value": "requiring intravenous [IV] antibiotics"
                                        }
                                    },
                                    {
                                        "exact_snippets": "Known active systemic bacterial infection (requiring intravenous [IV] antibiotics or fever >38.5°C at time of initiating study treatment)",
                                        "criterion": "active systemic bacterial infection",
                                        "requirement": {
                                            "requirement_type": "associated symptom",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 38.5,
                                                "unit": "°C"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "exact_snippets": "fungal infection",
                        "criterion": "fungal infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]",
                        "criterion": "detectable viral infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known human immunodeficiency virus positivity",
                        "criterion": "human immunodeficiency virus (HIV) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known active hepatitis B or C [for example, hepatitis B surface antigen positive]",
                        "criterion": "active hepatitis B or C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "12. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner until the end of treatment administration and for 16 weeks after the last dose of study drug.",
                "criterions": [
                    {
                        "exact_snippets": "For males of reproductive potential",
                        "criterion": "male reproductive potential",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        }
                    },
                    {
                        "exact_snippets": "For males of reproductive potential",
                        "criterion": "male reproductive potential",
                        "requirement": {
                            "requirement_type": "reproductive potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "use of condoms or other methods to ensure effective contraception with partner until the end of treatment administration and for 16 weeks after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "condoms",
                                "other methods to ensure effective contraception"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "use of condoms or other methods to ensure effective contraception with partner until the end of treatment administration and for 16 weeks after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from start of treatment to end of treatment administration"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 16,
                                        "unit": "weeks after last dose"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "o total bilirubin ≤1.5 X ULN. Participants with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.",
                "criterions": [
                    {
                        "exact_snippets": "total bilirubin ≤1.5 X ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted",
                        "criterion": "total bilirubin (in participants with Gilbert's syndrome)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "direct bilirubin within normal limits",
                        "criterion": "direct bilirubin (in participants with Gilbert's syndrome)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "within normal limits"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "total bilirubin \u001e1.5 X ULN",
                                "criterion": "total bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participants with Gilbert's syndrome with a total bilirubin \u001e2.0 times ULN and direct bilirubin within normal limits are permitted",
                                "criterion": "total bilirubin (in participants with Gilbert's syndrome)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2.0,
                                        "unit": "ULN"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "direct bilirubin within normal limits",
                                "criterion": "direct bilirubin (in participants with Gilbert's syndrome)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": "within normal limits"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Participants must be willing to receive prophylaxis with levetiracetam for the duration of study drug administration (or alternative anti-epileptic if agreed with Medical Monitor) 10. Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause.",
                "criterions": [
                    {
                        "exact_snippets": "Participants must be willing to receive prophylaxis with levetiracetam for the duration of study drug administration (or alternative anti-epileptic if agreed with Medical Monitor)",
                        "criterion": "willingness to receive anti-epileptic prophylaxis",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants must be willing to receive prophylaxis with levetiracetam for the duration of study drug administration (or alternative anti-epileptic if agreed with Medical Monitor)",
                        "criterion": "willingness to receive anti-epileptic prophylaxis",
                        "requirement": {
                            "requirement_type": "prophylactic medication",
                            "expected_value": [
                                "levetiracetam",
                                "alternative anti-epileptic if agreed with Medical Monitor"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Participants must be willing to receive prophylaxis with levetiracetam for the duration of study drug administration (or alternative anti-epileptic if agreed with Medical Monitor)",
                        "criterion": "willingness to receive anti-epileptic prophylaxis",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of study drug administration"
                        }
                    },
                    {
                        "exact_snippets": "Confirmed negative serum pregnancy test (β-hCG) before starting study treatment",
                        "criterion": "serum pregnancy test (β-hCG)",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Confirmed negative serum pregnancy test (β-hCG) before starting study treatment",
                        "criterion": "serum pregnancy test (β-hCG)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "before starting study treatment"
                        }
                    },
                    {
                        "exact_snippets": "participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "no longer of childbearing potential"
                        }
                    },
                    {
                        "exact_snippets": "participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": [
                                "surgical menopause",
                                "chemical menopause",
                                "natural menopause"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Serum creatinine ≤1.5 X ULN or estimated creatinine clearance ≥ 60 mL/min (calculated using Institutional standard method) 8. Participants with tumor-induced seizures must be well-controlled on a stable anti-epileptic treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Serum creatinine ≤1.5 X ULN",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "estimated creatinine clearance ≥ 60 mL/min (calculated using Institutional standard method)",
                        "criterion": "estimated creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants with tumor-induced seizures must be well-controlled on a stable anti-epileptic treatment.",
                        "criterion": "tumor-induced seizures",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "well-controlled"
                        }
                    },
                    {
                        "exact_snippets": "Participants with tumor-induced seizures must be well-controlled on a stable anti-epileptic treatment.",
                        "criterion": "tumor-induced seizures",
                        "requirement": {
                            "requirement_type": "anti-epileptic treatment stability",
                            "expected_value": "stable"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Serum creatinine \u00181.5 X ULN",
                                "criterion": "serum creatinine",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "X ULN"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "estimated creatinine clearance \u00181.5 X ULN (calculated using Institutional standard method)",
                                "criterion": "estimated creatinine clearance",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 60,
                                        "unit": "mL/min"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "not_criteria": {
                                    "exact_snippets": "Participants with tumor-induced seizures must be well-controlled on a stable anti-epileptic treatment.",
                                    "criterion": "tumor-induced seizures",
                                    "requirement": {
                                        "requirement_type": "control status",
                                        "expected_value": "well-controlled"
                                    }
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Participants with tumor-induced seizures must be well-controlled on a stable anti-epileptic treatment.",
                                        "criterion": "tumor-induced seizures",
                                        "requirement": {
                                            "requirement_type": "control status",
                                            "expected_value": "well-controlled"
                                        }
                                    },
                                    {
                                        "exact_snippets": "Participants with tumor-induced seizures must be well-controlled on a stable anti-epileptic treatment.",
                                        "criterion": "tumor-induced seizures",
                                        "requirement": {
                                            "requirement_type": "anti-epileptic treatment stability",
                                            "expected_value": "stable"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation until the end of treatment administration and for 16 weeks after the last dose of study drug.",
                "criterions": [
                    {
                        "exact_snippets": "For females of reproductive potential: use of highly effective contraception",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "contraception type",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "For females of reproductive potential: use of highly effective contraception",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "usage",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agreement to use such a method during study participation until the end of treatment administration and for 16 weeks after the last dose of study drug",
                        "criterion": "contraception use duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "from start of study participation until the end of treatment administration and for 16 weeks after the last dose of study drug"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "For females of reproductive potential",
                    "criterion": "females of reproductive potential",
                    "requirement": {
                        "requirement_type": "N/A",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "For females of reproductive potential: use of highly effective contraception",
                            "criterion": "contraception use",
                            "requirement": {
                                "requirement_type": "contraception type",
                                "expected_value": "highly effective"
                            }
                        },
                        {
                            "exact_snippets": "For females of reproductive potential: use of highly effective contraception",
                            "criterion": "contraception use",
                            "requirement": {
                                "requirement_type": "usage",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "agreement to use such a method during study participation until the end of treatment administration and for 16 weeks after the last dose of study drug",
                            "criterion": "contraception use duration",
                            "requirement": {
                                "requirement_type": "duration",
                                "expected_value": "from start of study participation until the end of treatment administration and for 16 weeks after the last dose of study drug"
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "1b. Arms A and B only: Participants who have had a prior resection of diagnosed glioma (2021 WHO grade IV), defined as participants who have progressed on or following standard therapy, which includes maximal surgical resection, temozolomide, and fractionated radiotherapy. Participants will also need to have radiation planned as part of the post-surgical treatment plan.",
                "criterions": [
                    {
                        "exact_snippets": "prior resection of diagnosed glioma (2021 WHO grade IV)",
                        "criterion": "prior resection of diagnosed glioma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior resection of diagnosed glioma (2021 WHO grade IV)",
                        "criterion": "prior resection of diagnosed glioma",
                        "requirement": {
                            "requirement_type": "WHO grade",
                            "expected_value": "2021 grade IV"
                        }
                    },
                    {
                        "exact_snippets": "participants who have progressed on or following standard therapy, which includes maximal surgical resection, temozolomide, and fractionated radiotherapy",
                        "criterion": "progression on or following standard therapy",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "participants who have progressed on or following standard therapy, which includes maximal surgical resection, temozolomide, and fractionated radiotherapy",
                        "criterion": "progression on or following standard therapy",
                        "requirement": {
                            "requirement_type": "standard therapy components",
                            "expected_value": [
                                "maximal surgical resection",
                                "temozolomide",
                                "fractionated radiotherapy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "radiation planned as part of the post-surgical treatment plan",
                        "criterion": "radiation in post-surgical treatment plan",
                        "requirement": {
                            "requirement_type": "planned",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* hemoglobin ≥9.0 g/dL Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.",
                "criterions": [
                    {
                        "exact_snippets": "hemoglobin ≥9.0 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.",
                        "criterion": "timing of initial treatment after erythrocyte transfusion",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "must not begin earlier than the day after erythrocyte transfusion"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "hemoglobin \u001e9.0 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.",
                        "criterion": "timing of initial treatment after erythrocyte transfusion",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "must not begin earlier than the day after erythrocyte transfusion"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelets (at time of surgery) ≥100,000/mcL",
                "criterions": [
                    {
                        "exact_snippets": "Platelets (at time of surgery) ≥100,000/mcL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mcL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets (at time of surgery) \u001e=100,000/mcL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mcL"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age. Patients stable on concomitant medications known to prolong the QT interval may be allowed to participate in the study provided that their mean resting corrected QT interval (QTcF) is < 470 msec at baseline and after discussion with the Medical Monitor.",
                "criterions": [
                    {
                        "exact_snippets": "Any factors that increase the risk of QTc prolongation or risk of arrhythmic events",
                        "criterion": "risk factors for QTc prolongation or arrhythmic events",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "heart failure",
                        "criterion": "heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "hypokalemia",
                        "criterion": "hypokalemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "congenital long QT syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "family history of long QT syndrome",
                        "criterion": "family history of long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "family history of ... unexplained sudden death under 40 years-of-age",
                        "criterion": "family history of unexplained sudden death under 40 years-of-age",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients stable on concomitant medications known to prolong the QT interval may be allowed ... provided that their mean resting corrected QT interval (QTcF) is < 470 msec at baseline",
                        "criterion": "mean resting corrected QT interval (QTcF) at baseline",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Any factors that increase the risk of QTc prolongation or risk of arrhythmic events",
                        "criterion": "risk factors for QTc prolongation or arrhythmic events",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "heart failure",
                        "criterion": "heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hypokalemia",
                        "criterion": "hypokalemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congenital long QT syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of long QT syndrome",
                        "criterion": "family history of long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of ... unexplained sudden death under 40 years-of-age",
                        "criterion": "family history of unexplained sudden death under 40 years-of-age",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patients stable on concomitant medications known to prolong the QT interval may be allowed ... provided that their mean resting corrected QT interval (QTcF) is < 470 msec at baseline",
                                "criterion": "mean resting corrected QT interval (QTcF) at baseline",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 470,
                                        "unit": "msec"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Patients stable on concomitant medications known to prolong the QT interval may be allowed ... provided that their mean resting corrected QT interval (QTcF) is < 470 msec at baseline",
                                "criterion": "mean resting corrected QT interval (QTcF) at baseline",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 470,
                                        "unit": "msec"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Pregnancy or lactation.",
                "criterions": [
                    {
                        "exact_snippets": "Pregnancy",
                        "criterion": "pregnancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "lactation",
                        "criterion": "lactation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Pregnancy",
                        "criterion": "pregnancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lactation",
                        "criterion": "lactation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year. If prior therapy in lifetime, then excluded if history of pulmonary toxicities from administration. Patients who have received treatment with nitrosoureas (e.g., BCNU, CCNU) in the year before study entry without experiencing lung toxicity are allowed on study.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year",
                        "criterion": "prior treatment with pneumotoxic drugs",
                        "requirement": {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year",
                        "criterion": "prior treatment with pneumotoxic drugs",
                        "requirement": {
                            "requirement_type": "drug examples",
                            "expected_value": [
                                "busulfan",
                                "bleomycin"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "If prior therapy in lifetime, then excluded if history of pulmonary toxicities from administration",
                        "criterion": "history of pulmonary toxicities from pneumotoxic drug administration",
                        "requirement": {
                            "requirement_type": "history of pulmonary toxicities",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients who have received treatment with nitrosoureas (e.g., BCNU, CCNU) in the year before study entry without experiencing lung toxicity are allowed on study",
                        "criterion": "prior treatment with nitrosoureas",
                        "requirement": {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients who have received treatment with nitrosoureas (e.g., BCNU, CCNU) in the year before study entry without experiencing lung toxicity are allowed on study",
                        "criterion": "prior treatment with nitrosoureas",
                        "requirement": {
                            "requirement_type": "drug examples",
                            "expected_value": [
                                "BCNU",
                                "CCNU"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Patients who have received treatment with nitrosoureas (e.g., BCNU, CCNU) in the year before study entry without experiencing lung toxicity are allowed on study",
                        "criterion": "prior treatment with nitrosoureas",
                        "requirement": {
                            "requirement_type": "lung toxicity",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Cardiac dysfunction defined as: Myocardial infarction within six months of study entry, NYHA Class II/III/IV heart failure, unstable angina or unstable cardiac arrhythmias.",
                "criterions": [
                    {
                        "exact_snippets": "Myocardial infarction within six months of study entry",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "NYHA Class II/III/IV heart failure",
                        "criterion": "heart failure (NYHA class)",
                        "requirement": {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "II",
                                "III",
                                "IV"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "unstable angina",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unstable cardiac arrhythmias",
                        "criterion": "unstable cardiac arrhythmias",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}